-- Robert Preidt
WEDNESDAY, Aug. 28 (HealthDay News) -- Certain radiation and
chemotherapy treatments may increase Hodgkin lymphoma survivors'
risk of developing stomach cancer, according to new study.
Hodgkin lymphoma is a cancer of the immune system and is one of
the most common cancers among teens and young adults in the United
States. Advances in treatment have led to improvements in survival.
Between 2003 and 2009, the five-year survival rate was 88
Past research, however, has linked radiation and chemotherapy
treatments to stomach cancer risk in survivors, but those studies
were limited in scope. To learn more about the link between these
treatments and stomach cancer risk, researchers from the U.S.
National Cancer Institute examined data from more than 17,400
Hodgkin lymphoma survivors in the United States, Canada, the
Netherlands, Denmark, Finland, Norway and Sweden who were diagnosed
between 1953 and 2003.
Of those survivors, 89 were found to have later developed
The analysis revealed that the risk of stomach cancer rose with
increasing doses of radiation to the stomach. Patients who received
the highest radiation doses were nearly three times more likely to
develop stomach cancer than those who received the lowest
The risks of stomach cancer associated with radiation were even
higher for patients who also received the alkylating agent
procarbazine, a type of chemotherapy known to damage DNA. Stomach
cancer risks were highly dependent on the doses of both radiation
This is the first study to provide clear evidence of a strong
interaction between chemotherapy and radiation on Hodgkin lymphoma
survivors' risk for stomach cancer, the researchers said. It did
not, however, prove a cause-and-effect relationship between the
The study also suggested an increased stomach cancer risk for
patients who received a similar alkylating agent called
dacarbazine, which is now commonly used to treat Hodgkin lymphoma.
However, more research is needed to confirm this link, the
No other alkylating agent was associated with an increased risk
of stomach cancer, according to the study, which was published Aug.
26 in the
Journal of Clinical Oncology.
"Our study adds strong support to the growing concern that stomach cancer is a rare but important adverse late effect of treatment for Hodgkin lymphoma," Lindsay Morton, of the National Cancer Institute's Division of Cancer Epidemiology and Genetics, said in an institute news release.
"Because Hodgkin lymphoma patients commonly receive treatment in their 20s and 30s, many of the stomach cancers arise before age 50, nearly 20 years earlier than is typical for newly diagnosed patients who have never had cancer," Morton said. "Clinicians who follow these survivors should be alert to patient complaints related to the gastrointestinal tract."
The Leukemia & Lymphoma Society has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.